Revance Therapeutics and Crown Laboratories have again extended the deadline for Crown to launch its $700 million tender offer for Revance. Revance on Tuesday said Crown now has until Nov. 19 to begin ...

Revance Therapeutics (NASDAQ:RVNC) surged 15% after Crown Laboratories extended its tender offer for a week. The tender offer is extended until Nov. 19, according to an 8-K filing earlier on Tuesday.

Equities researchers at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a ...

Mizuho has recently reduced Revance Therapeutics Inc (RVNC) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on January 9, 2024, Goldman had reduced the stock ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Hold rating on Revance Therapeutics (RVNC – Research ...

Nashville-based Revance Therapeutics saw its stock price plummet by almost 40 percent Friday following the company's third ...

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Revance Therapeutics (RVNC – Research Report), with a price target of $6.60. Douglas Tsao’s rating is based on ...

Swiss company Teoxane claimed that Revance, which focuses on neuromodulators related to aesthetics, breached a 2020 ...

Revance Therapeutics (RVNC) faces challenges as doubts over its ability to continue as a going concern arise, leading to a 16% drop in after hours trading.

If you are an Outbrain shareholder, click here to learn more about your rights and options . Revance Therapeutics, Inc. (NASDAQ: RVNC )'s sale to Crown Laboratories, Inc. for $6.66 per share in cash.

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago. These ...